Bram Vanparys is a Partner at Gimv, a leading European venture capital firm. See sector focus and contact routes.
Bram Vanparys is a Partner at Gimv, a leading European venture capital firm, where he joined in 2018 after more than 14 years of international venture capital experience, including a role at Merck Ventures in Amsterdam. His investment thesis centers on life sciences, with a focus on startups in Europe and Israel that he has helped launch, finance, or exit, such as arGEN-X, Multiplicom, Calypso Biotech, and iOmx. While specific check sizes and lead/follow behavior are not publicly detailed, Vanparys serves on the boards of multiple life sciences portfolio companies, including ImCheck Therapeutics, iSTAR Medical, Kinaset Therapeutics, and Topas Therapeutics. Notable portfolio companies under his involvement include arGEN-X (now ARGX), which is publicly listed, and Multiplicom, acquired by Amatsigroup (now Eurofins). Vanparys holds a doctorate and is recognized for his successful track record in life science investments across Europe and Israel, though no distinctive public writing or unique point of view is documented in available sources.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Amsterdam.
Investors like Bram Vanparys · Full investor directory · Investor access · Company funding database